Oligonucleotide Delivery System Market
完整報告名稱與涵蓋範圍
Oligonucleotide Delivery System Market Size, Share & Trends Analysis Distribution by Delivery System (Conjugation-Based Delivery Systems (GALNAc Conjugation, Ligand Conjugation, Antibody Conjugation, Targeting Moiety Conjugation), Nanoparticle-Based Delivery Systems (Lipid Nanoparticles (LNPs), Peptide Nanoparticles), Viral Vector-Based Delivery Systems (Adeno-associated Virus (AAV) Vectors, AAV9, Lentiviral Vectors, Others), Exosome-Based Delivery Systems, Liposomes, Others), Disease Indication and Segment Forecasts, 2024-2031
報告摘要
The Oligonucleotide Delivery System Market is positioned for steady expansion, with a projected CAGR of 12.4% from 2024 to 2031.
The Oligonucleotide Delivery System sector involves The delivery system of an oligonucleotide involves dynamics.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, propelled by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Oligonucleotide Delivery System Market Snapshot
Chapter 4. Global Oligonucleotide Delivery System Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Oligonucleotide Delivery System Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Oligonucleotide Delivery System Industry Trends
Chapter 5. Oligonucleotide Delivery System Market Segmentation 1: By Delivery System, Estimates & Trend Analysis
5.1. Market Share by Delivery System, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Delivery System:
5.2.1. Conjugation-Based Delivery Systems
5.2.1.1. GALNAc Conjugation
5.2.1.2. Ligand Conjugation
5.2.1.3. Antibody Conjugation
5.2.1.4. Targeting Moiety Conjugation
5.2.2. Nanoparticle-Based Delivery Systems
5.2.2.1. Lipid Nanoparticles (LNPs)
5.2.2.2. Peptide Nanoparticles
5.2.3. Viral Vector-Based Delivery Systems
5.2.3.1. Adeno-associated Virus (AAV) Vectors
5.2.3.2. AAV9
5.2.3.3. Lentiviral Vectors
5.2.3.4. Others
5.2.4. Exosome-Based Delivery Systems
5.2.5. Liposomes
5.2.6. Others
Chapter 6. Oligonucleotide Delivery System Market Segmentation 2: By Disease Indication, Estimates & Trend Analysis
6.1. Market Share by Disease Indication, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Disease Indications:
6.2.1. Genetic Disorders
6.2.2. Infectious Diseases
6.2.3. Oncology
6.2.4. Neurological Disorders
6.2.5. Others (Autoimmune Diseases, Metabolic Disorders, etc.)
Chapter 7. Oligonucleotide Delivery System Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. Global Oligonucleotide Delivery System Market, Regional Snapshot 2023 & 2031
7.2. North America
7.2.1. North America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.2.3. North America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031
7.3. Europe
7.3.1. Europe Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.3.3. Europe Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031
7.4. Asia Pacific
7.4.1. Asia Pacific Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Hong Kong
7.4.1.7. Southeast Asia
7.4.1.8. Rest of Asia Pacific
7.4.2. Asia Pacific Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.4.3. Asia Pacific Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031
7.5. Latin America
7.5.1. Latin America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.5.3. Latin America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031
7.6. Middle East & Africa
7.6.1. Middle East & Africa Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.6.1.1. GCC Countries
7.6.1.2. Israel
7.6.1.3. South Africa
7.6.1.4. Rest of Middle East and Africa
7.6.2. Middle East & Africa Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.6.3. Middle East & Africa Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Biogen
8.2.1.1. Business Overview
8.2.1.2. Key Product/Service Offerings
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. Sarepta Therapeutics, Inc.
8.2.3. Jazz Pharmaceuticals plc
8.2.4. Ionis Pharmaceuticals, Inc.
8.2.5. Nippon Shinyaku Co., Ltd.
8.2.6. AstraZeneca
8.2.7. Alnylam Pharmaceuticals, Inc.
8.2.8. Novartis AG
8.2.9. Dicerna Pharmaceuticals, Inc. (Novo Nordisk)
8.2.10. IVERIC bio, Inc. (Astellas Pharma Inc.)
8.2.11. Elsie Biotechnologies (GSK)
8.2.12. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們